All In Biotech

Drug Trial Radar · NCT07216378

Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat

On Demand Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With Hereditary Angioedema (HAE) With Sebetralstat

Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Available

Status

Available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
KalVista Pharmaceuticals, Ltd.Industry
Sponsor type
Industry
First posted
Oct 14, 2025

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes, from 2 years, up to 11 years

Summary

As written by the sponsor on the registry.

The sebetralstat Early Access Program (EAP) provides early access to the investigational medicinal product (IMP) sebetralstat to eligible and approved Hereditary Angioedema (HAE) pediatric (ages 2-11) post-trial and naïve patients for the on-demand treatment of angioedema attacks where the treating Physician determines they might benefit from this treatment.

Conditions

  • Hereditary Angioedema

Interventions

  • SebetralstatDrug

    Oral Plasma Kallikrein Inhibator

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • KalVista Investigative Site

    San Diego, California · Available

  • KalVista Investigative Site

    Evansville, Indiana · Available

  • KalVista Investigative Site

    Wheaton, Maryland · Available

  • KalVista Investigative Site

    St Louis, Missouri · Available

  • KalVista Investigative Site

    Knoxville, Tennessee · Available

  • KalVista Investigative Site

    San Antonio, Texas · Available

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.